Home › Therapeutic areas › Infectious Disease
Infectious Disease (21 companies · 24 conditions)
Conditions
Hepatitis B 5 COVID-19 4 Influenza 3 HIV 2 Pneumococcal Pneumonia 2 RSV 2 BK Virus Infection 1 Rare Chagas Disease 1 Cholera 1 Chronic Hepatitis Delta 1 Rare Community-Acquired Pneumonia 1 Cytomegalovirus Infection 1 Group A Streptococcal Infection 1 Hepatitis C 1 Invasive Fungal Infection 1 Invasive Pneumococcal Disease 1 Leishmaniasis 1 Melioidosis 1 Mycobacterium abscessus Lung Disease 1 Rare Mycobacterium avium Complex Lung Disease 1 Rare Nontuberculous Mycobacterial Lung Disease 1 Rare Shigellosis 1 Surgical Site Infection 1 Vulvovaginal Candidiasis 1
Companies
| Ticker | Company | Therapeutic areas | In Infectious Disease | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 2 | Approved | $3.02B | 4 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 3 | Phase 2 | $161M | 6 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 1 | Approved | $1.93B | 4 |
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $489M | 2 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 5 | Approved | $253M | 8 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 1 | Approved | $61.4M | 16 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 2 | Approved | $1.44B | 12 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 3 | Approved | $26.7B | 15 |
| IVVD | Invivyd | Infectious Disease | 4 | Approved | $152M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $4.49B | 29 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 4 | Phase 3 | $257M | 12 |
| PYPD | PolyPid | Infectious DiseaseMetabolic+1 | 1 | NDA Submitted | $138M | 4 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $197M | 5 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 4 | Approved | $28.4M | 5 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 1 | Phase 2 | $261M | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 6 | Phase 3 | $9.40B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $1.89B | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | $1.58B | 6 |
No companies match.